Cannabis Effects on Opioid Self-Administration

Part of paid clinical trials in Lexington, Kentucky.

Sponsor
Shanna Babalonis, PhD
Study ID
NCT07668635
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Cannabis Use
  • Opioid Use Disorder

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Not accepted

Interventions

  • Cannabis — DRUG
    Cannabis is administered three times daily during the active cannabis treatment period.
  • Placebo Cannabis — DRUG
    Matched placebo cannabis is administered three times daily during the placebo treatment period.
  • Intranasal Opioid Agonist — DRUG
    Intranasal opioid agonists are administered during sample and self-administration sessions
  • Oral Opioid Agonist — DRUG
    Oral opioid agonist maintenance doses are administered four times daily throughout study participation.

Study Details

The study will enroll participants with opioid use disorder and participants will reside at the University of Kentucky Hospital for this 6-week inpatient trial. During this time, double-blind doses of cannabis and opioids will be administered. The goal of the project is to determine if cannabis can alter the drive/desire to take opioids.

Key Dates

Start date
Jul 30, 2026
Status verified
Jun 2026
Primary completion
Jul 30, 2030
Completion
Jul 30, 2031

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Active Cannabis
    Participants receive active cannabis three times daily for approximately 16 days during one crossover treatment period. During this period, participants complete sample and self-administration sessions evaluating placebo and active intranasal opioid administration.
  • Placebo Comparator: Placebo Cannabis
    Participants receive placebo cannabis three times daily for approximately 16 days during one crossover treatment period. During this period, participants complete sample and self-administration sessions evaluating placebo and active intranasal opioid administration.

Primary Outcome Measure

Number of Opioid Self-Administration Trials Completed [ Time Frame: Up to 6.5 Weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Kentucky Center on Drug and Alcohol ResearchLexingtonKentucky40508-

Find similar trials in Lexington, KY

By research site
University of Kentucky Center on Drug and Alcohol Research· Lexington, KY

Related Studies